Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride
- Conditions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 43
- Registration Number
- NCT00633425
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1560
- Registration Number
- NCT00622284
- Locations
- 🇺🇸
1218.20.10030 Boehringer Ingelheim Investigational Site, Topeka, Kansas, United States
🇺🇸1218.20.10035 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸1218.20.10003 Boehringer Ingelheim Investigational Site, Chula Vista, California, United States
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT00620282
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Rochester, Minnesota, United States
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 260
- Registration Number
- NCT00619697
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Maribor, Slovenia
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 929
- Registration Number
- NCT00614120
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Suwon, Korea, Republic of
Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia
- Conditions
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 32
- Registration Number
- NCT00608179
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT00562250
- Locations
- 🇦🇷
Local Institution, Vicente Lopez, Buenos Aires, Argentina
Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 75
- Registration Number
- NCT00562172
- Locations
- 🇰🇷
Sanofi-aventis, Seoul, Korea, Republic of
Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 174
- Registration Number
- NCT00469586
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Konya, Turkey
Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 480
- Registration Number
- NCT00469092
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.